Eugene P. Kennedy's Net Worth
$49.1 Thousand
Who is Eugene P. Kennedy?
Eugene P. Kennedy does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include NEWLINK GENETICS CORP, and Galera Therapeutics, Inc..
SEC CIK
Eugene P. Kennedy's CIK is 0001721685
Past Insider Trading and Trends
2019 was Eugene P. Kennedy's most active year for acquiring shares with 34 total transactions. Eugene P. Kennedy's most active month to acquire stocks was the month of June. 2019 was Eugene P. Kennedy's most active year for disposing of shares, totalling 12 transactions. Eugene P. Kennedy's most active month to dispose stocks was the month of June. 2019 saw Eugene P. Kennedy paying a total of $0.00 for 408,254 shares, this is the most they've acquired in one year. In 2018 Eugene P. Kennedy cashed out on 494 shares for a total of $4,847.24, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
NEWLINK GENETICS CORP (LUMO) Snapshot price: $3.7
Chief Medical OfficerEugene P. Kennedy owns 11,423 units of Common Stock which is worth $42,265.10. In the year 2017 Eugene P. Kennedy acquired a total of 9,939 shares in NEWLINK GENETICS CORP, Eugene also disposed a total of 1,605 shares of NEWLINK GENETICS CORP equalling to $6,824.63.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +8.96% | 939 |
—
|
—
| 11.42K |
Feb 1
| |||
Form 4
| +606.47% | 9K |
—
|
—
| 10.48K |
Apr 1
| |||
Form 4
| -2.67% | -376.00 |
$2.21 | -$830.96 | 13.72K |
Jan 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 31
| |||
Form 4
| -2.48% | -359.00 |
$1.57 | -$563.63 | 14.1K |
Jun 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
| -2.71% | -376.00 |
$1.55 | -$582.80 | 13.52K |
Jan 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 9
| |||
Form 4
| -0.61% | -85.00 |
$8.62 | -$732.70 | 13.89K |
Jan 20
| |||
Form 4
| -2.84% | -409.00 |
$10.06 | -$4,114.54 | 13.98K |
Jan 4
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Galera Therapeutics, Inc. (GRTX) Snapshot price: $0.0749
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||